Siqing Fu

15.0k total citations
412 papers, 9.6k citations indexed

About

Siqing Fu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Siqing Fu has authored 412 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 229 papers in Oncology, 136 papers in Molecular Biology and 123 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Siqing Fu's work include Cancer Genomics and Diagnostics (75 papers), Lung Cancer Treatments and Mutations (65 papers) and Colorectal Cancer Treatments and Studies (57 papers). Siqing Fu is often cited by papers focused on Cancer Genomics and Diagnostics (75 papers), Lung Cancer Treatments and Mutations (65 papers) and Colorectal Cancer Treatments and Studies (57 papers). Siqing Fu collaborates with scholars based in United States, China and Canada. Siqing Fu's co-authors include Razelle Kurzrock, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Filip Jankú, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha‐Paul, Rajyalakshmi Luthra and Vivek Subbiah and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Siqing Fu

389 papers receiving 9.4k citations

Peers

Countries citing papers authored by Siqing Fu

Since Specialization

Citations

This map shows the geographic impact of Siqing Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siqing Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siqing Fu more than expected).

Fields of papers citing papers by Siqing Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siqing Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siqing Fu. The network helps show where Siqing Fu may publish in the future.

Co-authorship network of co-authors of Siqing Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Siqing Fu. A scholar is included among the top collaborators of Siqing Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siqing Fu. Siqing Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody 2021 ·Clinical Cancer Research ·James J. Harding, Víctor Moreno, Yung‐Jue Bang, Min Hee Hong, Amita Patnaik, José Trigo, Anna M. Szpurka, Noboru Yamamoto, Toshihiko Doi, Siqing Fu, Boris Calderón, Nieves Vélez de Mendizábal, Emiliano Calvo, Danni Yu, Leena Gandhi, (unknown), Violeta Régnier Galvão, Ching Ching Leow, Maria J. de Miguel	116
2	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors 2019 ·Clinical Cancer Research ·Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, (unknown), Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, Ghazaleh Eskandari, Daniel V.T. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese‐Hamim, Pascal Girard, Samer El Bawab, David S. Hong	67
3	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer 2019 ·Clinical Cancer Research ·(unknown), Kenneth R. Hess, Filip Jankú, Nora Sánchez, Kenna Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, Funda Meric‐Bernstam	40
4	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition 2018 ·Clinical Cancer Research ·Xian Chen, (unknown), Angela Alexander, Yufeng Jiang, Cansu Karakaş, Kenneth R. Hess, Jason P.W. Carey, Tuyen Bui, Smruthi Vijayaraghavan, Kurt W. Evans, Min Yi, (unknown), Kwok‐Leung Cheung, Ian O. Ellis, Siqing Fu, Funda Meric‐Bernstam, Kelly K. Hunt, Khandan Keyomarsi	78
5	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act 2017 ·Clinical Cancer Research ·Kenneth L. Kehl, (unknown), Siqing Fu, Goldy C. George, Kenneth R. Hess, Filip Jankú, Daniel D. Karp, Shumei Kato, (unknown), Razelle Kurzrock, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Vivek Subbiah, Apostolia M. Tsimberidou, David S. Hong	4
6	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells 2016 ·Clinical Cancer Research ·Chad Tang, James W. Welsh, Patricia M. de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel D. Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong	251
7	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics 2016 ·Molecular Cancer Therapeutics ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, (unknown), Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	73
8	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study 2016 ·Cancer Research ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, (unknown), Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	149
9	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma 2015 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqing Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Goldy C. George, Lucy T. Xu, Robert Shumaker, Min Ren, (unknown), Cynthia Bedell, Corina Andresen, Perminder S. Sachdev, James P. O'Brien, John Nemunaitis	57
10	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents 2014 ·Molecular Cancer Therapeutics ·Prasanth Ganesan, Stacy L. Moulder, J. Jack Lee, Filip Jankú, Vicente Valero, Ralph Zinner, Aung Naing, Siqing Fu, Apostolia M. Tsimberidou, David S. Hong, Bettzy Stephen, Philip Stephens, Roman Yelensky, Funda Meric‐Bernstam, Razelle Kurzrock, Jennifer J. Wheler	29
11	Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic 2014 ·Clinical Cancer Research ·Denis L. Jardim, Chad Tang, Débora De Melo Gagliato, Gerald S. Falchook, Kenneth R. Hess, Filip Jankú, Siqing Fu, Jennifer J. Wheler, Ralph Zinner, Aung Naing, Apostolia M. Tsimberidou, (unknown), (unknown), Sinchita Roy‐Chowdhuri, Raja Luthra, Ravi Salgia, Razelle Kurzrock, Funda Meric‐Bernstam, David S. Hong	65
12	Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial 2013 ·Clinical Cancer Research ·Ana M. González-Angulo, Funda Meric‐Bernstam, Sant P. Chawla, Gerald S. Falchook, David S. Hong, Argun Akçakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer J. Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, Razelle Kurzrock	63
13	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations 2013 ·Molecular Cancer Therapeutics ·Prasanth Ganesan, Filip Jankú, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha‐Paul, Siqing Fu, Vanda M. Stepanek, J. Jack Lee, Rajyalakshmi Luthra, Michael J. Overman, Scott Kopetz, Robert A. Wolff, Razelle Kurzrock	38
14	Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents 2012 ·Molecular Cancer Therapeutics ·Liang Zheng, Yan Long, Wen-Bin Tsai, Siqing Fu, Razelle Kurzrock, (unknown), Fan Zhang, Helen H.W. Chen, Bryan T. Hennessy, Gordon B. Mills, Niramol Savaraj, Macus Tien Kuo	67
15	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative 2012 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock	387
16	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience 2012 ·Clinical Cancer Research ·Jennifer J. Wheler, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Stacy L. Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock	77
17	Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors 2012 ·Clinical Cancer Research ·Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph A. Ludwig, Helen X. Chen, L. Austin Doyle, Razelle Kurzrock	163
18	PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors 2011 ·Molecular Cancer Therapeutics ·Filip Jankú, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock	289
19	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience 2011 ·The Oncologist ·Hazem El‐Osta, David S. Hong, Jennifer J. Wheler, Siqing Fu, Aung Naing, Gerald S. Falchook, Marshall E. Hicks, Sijin Wen, Apostolia M. Tsimberidou, Razelle Kurzrock	53
20	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment 2010 ·Clinical Cancer Research ·Ignacio Garrido‐Laguna, Filip Jankú, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, (unknown), Xuemei Wang, Merrill S. Kies, Razelle Kurzrock	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact